Structured around addressing a significant gap in the drug development process from post discovery and animal efficacy models to clinical phase. the Lamassu Bio team are capitalizing on their expertise in early translational research to bring products to Phase I/II clinical trial. In partnership with the Mayo Clinic. the firm's first drug - RABI767 - is a novel small molecule therapy for acute pancreatitis developed at Mayo Clinic by leading scientists -- usefully understood as having profound efficacy completely to mitigate mortality and morbidity associated with severe acute pancreatitis in animal models. Acute pancreatitis is a leading cause in the US of emergency department visits and gastrointestinal admissions with over 330,000 hospital admissions per year in US with significant mortality and long-term complications. The ultimate goal of Lamassu Bio's team is to the lives of patients afflicted with this disease, and improving the quality of life for survivors.
